Skip to main content
Gland Pharma Limited logo

Gland Pharma Limited — Investor Relations & Filings

Ticker · GLAND ISIN · INE068V01023 LEI · 335800JJVDY5R6KF5K34 BSE.NS Manufacturing
Open in API
Filings indexed 680 across all filing types
Latest filing 2022-10-28 Regulatory Filings
Country IN India
Listing BSE.NS GLAND

About Gland Pharma Limited

https://glandpharma.com

Gland Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) focused on injectable formulations. The company operates primarily through a business-to-business (B2B) model, providing development and manufacturing services for a diverse range of sterile injectables. Its portfolio encompasses complex generics across various therapeutic areas, including oncology, ophthalmology, anti-infectives, and orthopedics. Gland Pharma maintains a vertically integrated supply chain, ensuring control over critical raw materials and active pharmaceutical ingredients. The company serves a global market, with a significant presence in regulated regions such as the United States, Europe, Canada, and Australia. Its manufacturing facilities adhere to international quality standards and hold approvals from major regulatory bodies. Key strengths include expertise in niche segments like heparin and enoxaparin, alongside a robust pipeline of complex delivery systems.

Recent filings

Filing Released Lang Actions
Schedule of Analysts/Institutional Investor Meet/Con. Call
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges notifying them of the schedule of analyst and institutional investor meetings. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulation 30, which pertains to disclosure of material events. The content is an announcement of upcoming investor meetings, not a financial report, earnings release, or detailed presentation. The document length is short (1531 characters), and it serves as an informational notice rather than a report or transcript. Therefore, it fits best under the category of Investor Presentation (IP) or Regulatory Filings (RNS). However, since it is only a schedule notification and not the presentation itself, it is more appropriate to classify it as Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2022-10-28 English
Newspaper Advertisements
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the publication of a newspaper advertisement for the unaudited financial results of Q2 FY 2023. It references Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, which mandates disclosure of financial results. The document includes copies of the newspaper advertisements but does not contain the actual financial statements or detailed financial analysis. The document length is short (1651 characters), and it primarily serves as an announcement or notification about the publication of financial results rather than the results themselves. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement rather than an Interim/Quarterly Report (IR) or Earnings Release (ER).
2022-10-27 English
Recording of Analysts/Institutional Investor Meet/Con. Call
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the earnings call for the quarter and half year ended September 30, 2022. It mentions the date and time of the earnings call and provides a weblink to the audio recording. The document does not contain the transcript or detailed financial results but is an announcement about the earnings call recording. The document length is short (1370 characters), and it serves as a notification rather than the full transcript or financial report. Therefore, it fits best under the category of Call Transcript (CT) as it relates to the earnings call, but since it only announces the recording and does not provide the transcript itself, it is more appropriate to classify it as a Regulatory Filing (RNS) because it is a regulatory announcement about the earnings call recording, not the transcript or financial results themselves.
2022-10-26 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is titled as an "Investor Presentation on Q2FY23 (Quarter and Half Year ended September 30, 2022) Financial Results" and is addressed to stock exchanges. It contains detailed financial highlights, including revenue, EBITDA, PBT, PAT, segment performance, geographic expansion, and product pipeline updates. The document is dated October 26, 2022, and covers the quarter and half-year ended September 30, 2022, which aligns with a quarterly financial update. The content is structured as a presentation with charts, tables, and forward-looking statements, typical of investor presentations. It is not a full annual report, audit report, or earnings release summary but a detailed presentation for investors. Therefore, the document fits the category of an Investor Presentation (IP). The document length (12,469 characters) supports it being a full presentation rather than a brief announcement or certification.
2022-10-26 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated October 26, 2022, announcing the Q2FY23 (quarter and half year ended September 30, 2022) financial results of Gland Pharma Limited. It contains detailed financial data including revenue, EBITDA, PBT, PAT, segment-wise revenue, R&D expenses, and capex for the quarter and half year. It also mentions an earnings call scheduled for the same day to discuss the results. The document is not a full annual or interim report but a financial results announcement with key highlights and some financial metrics. It is not a transcript of the earnings call, but it references the call. The document fits the definition of an Earnings Release (ER) as it is the initial announcement of quarterly financial results with key highlights. The document length (10,721 characters) and content confirm it is a full release, not just a brief announcement or certification. Therefore, the correct classification is ER with high confidence. Q2 2023
2022-10-26 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 100% confidence The document is a detailed communication from Gland Pharma Limited to stock exchanges regarding the outcome of a Board Meeting held on October 26, 2022. It specifically mentions the approval of unaudited financial results (standalone and consolidated) for the quarter and half year ended September 30, 2022, along with the Limited Review Report. The document includes the Independent Auditor's Review Report pursuant to SEBI regulations and detailed unaudited consolidated financial results with comparative figures. The presence of comprehensive financial data, including income, expenses, profit before tax, tax expense, and profit for the period, confirms this is a financial report for a period shorter than a full fiscal year. The document is not merely an announcement or a certification but contains substantive financial data and analysis. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2022-10-26 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.